Preoperative thrombocytosis is a significant unfavorable prognostic factor for patients with resectable non-small cell lung cancer

World Journal of Surgical Oncology

Jong Seok Lee⁴  Jin-Haeng Chung³  Kwhanmien Kim²  Sanghoon Jheon²  Jae-Ho Lee¹  Choon-Taek Lee¹  Yu Jung Kim¹  Hee Chul Yang²  Hyun Chang¹  Miso Kim¹ 

[1] Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea;Department of Thoracic Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea;Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea;Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, 166 Gumi-ro, Bundang-gu, Seongnam, Gyeonggi-do 463-707, Republic of Korea

关键词: Survival;    Recurrence;    Prognosis;    Thrombocytosis;    Platelet count;    Non-small cell lung cancer;   

Others  :  820354
DOI  :  10.1186/1477-7819-12-37

 received in 2013-08-09, accepted in 2014-01-28,  发布年份 2014

【 摘 要 】

Background

Previous studies have reported that pretreatment thrombocytosis is associated with poor outcomes in several cancer types. This study was designed to evaluate the prognostic significance of preoperative thrombocytosis in patients with non-small cell lung cancer (NSCLC) who undergo surgery.

Methods

We retrospectively reviewed the records of 199 patients who underwent R0 resection for NSCLC between May 2003 and July 2006 at Seoul National University Bundang Hospital, Seongnam, Korea.

Results

The frequency of preoperative thrombocytosis was 7.5% (15/199). Patients with preoperative thrombocytosis had shorter overall survival (OS, P = 0.003) and disease-free survival (DFS, P = 0.005) than those without thrombocytosis. In multivariable analysis, patients with preoperative thrombocytosis had a significantly greater risk of death and recurrence than those without preoperative thrombocytosis (risk of death: hazard ratio (HR) 2.98, 95% confidence interval (CI) 1.39 to 6.37, P = 0.005; risk of recurrence: HR 2.47, 95% CI 1.22 to 5.01, P = 0.012). A tendency towards a shorter OS and DFS was observed in three patients with persistent thrombocytosis during the follow-up period when compared with those of patients who recovered from thrombocytosis after surgery.

Conclusions

Preoperative thrombocytosis was valuable for predicting the prognosis of patients with NSCLC. Special attention should be paid to patients with preoperative and postoperative thrombocytosis.

【 授权许可】

   
2014 Kim et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
• [2]Deng Q, Yang H, Zhang X, Chen H, Qiu Y, Wen D, Xiong X, Wang W, He J: Correlation between pre-treatment anemia and prognosis in non-small cell lung cancer patients. Zhongguo Fei Ai Za Zhi 2010, 13:722-726.
• [3]Holgersson G, Sandelin M, Hoye E, Bergstrom S, Henriksson R, Ekman S, Nyman J, Helsing M, Friesland S, Holgersson M, Lundström KL, Janson C, Birath E, Mörth C, Blystad T, Ewers SB, Löden B, Bergqvist M: Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer. Med Oncol 2012, 29:3176-3182.
• [4]Maione P, Rossi A, Di Maio M, Gridelli C: Tumor-related leucocytosis and chemotherapy-induced neutropenia: linked or independent prognostic factors for advanced non-small cell lung cancer? Lung Cancer 2009, 66:8-14.
• [5]Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T: Prognostic impact of thrombocytosis in resectable non-small cell lung cancer. Interact Cardiovasc Thorac Surg 2008, 7:613-615.
• [6]Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T: Preoperative leukocytosis, anemia and thrombocytosis are associated with poor survival in non-small cell lung cancer. Anticancer Res 2009, 29:2687-2690.
• [7]Xu C, Gao Y, Li L, Xing L, Liu S: Impact of anemia on chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2010, 13:968-974.
• [8]Van Tiel E, Peeters PH, Smit HA, Nagelkerke NJ, Van Loon AJ, Grobbee DE, Bueno-de-Mesquita HB: Quitting smoking may restore hematological characteristics within five years. Ann Epidemiol 2002, 12:378-388.
• [9]Tell GS, Grimm RH Jr, Vellar OD, Theodorsen L: The relationship of white cell count, platelet count, and hematocrit to cigarette smoking in adolescents: the Oslo Youth Study. Circulation 1985, 72:971-974.
• [10]Roethig HJ, Koval T, Muhammad-Kah R, Jin Y, Mendes P, Unverdorben M: Short term effects of reduced exposure to cigarette smoke on white blood cells, platelets and red blood cells in adult cigarette smokers. Regul Toxicol Pharmacol 2010, 57:333-337.
• [11]Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF: Systemic effects of smoking. Chest 2007, 131:1557-1566.
• [12]Tranum BL, Haut A: Thrombocytosis: platelet kinetics in neoplasia. J Lab Clin Med 1974, 84:615-619.
• [13]Sierko E, Wojtukiewicz MZ: Platelets and angiogenesis in malignancy. Semin Thromb Hemost 2004, 30:95-108.
• [14]Hernandez E, Donohue KA, Anderson LL, Heller PB, Stehman FB: The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2000, 78:137-142.
• [15]Scholz HS, Petru E, Gucer F, Haas J, Tamussino K, Winter R: Preoperative thrombocytosis is an independent prognostic factor in stage III and IV endometrial cancer. Anticancer Res 2000, 20:3983-3985.
• [16]Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf SK, et al.: Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012, 366:610-618.
• [17]Hwang SG, Kim KM, Cheong JH, Kim HI, An JY, Hyung WJ, Noh SH: Impact of pretreatment thrombocytosis on blood-borne metastasis and prognosis of gastric cancer. Eur J Surg Oncol 2012, 38:562-567.
• [18]Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Satomi T: Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 2002, 9:287-291.
• [19]Shimada H, Oohira G, Okazumi S, Matsubara H, Nabeya Y, Hayashi H, Takeda A, Gunji Y, Ochiai T: Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg 2004, 198:737-741.
• [20]Cravioto-Villanueva A, Luna-Perez P, Gutierrez-de la Barrera M, Martinez-Gomez H, Maffuz A, Rojas-Garcia P, Perez-Alvarez C, Rodriguez-Ramirez S, Rodriguez-Antezana E, Ramirez-Ramirez L: Thrombocytosis as a predictor of distant recurrence in patients with rectal cancer. Arch Med Res 2012, 43:305-311.
• [21]Kawai K, Kitayama J, Tsuno NH, Sunami E, Watanabe T: Thrombocytosis before pre-operative chemoradiotherapy predicts poor response and shorter local recurrence-free survival in rectal cancer. Int J Colorectal Dis 2013, 28:527-535.
• [22]Gonzalez Barcala FJ, Garcia Prim JM, Moldes Rodriguez M, Alvarez Fernandez J, Rey Rey MJ, Pose Reino A, Valdes Cuadrado L: Platelet count: association with prognosis in lung cancer. Med Oncol 2010, 27:357-362.
• [23]Lee M, Kim SW, Nam EJ, Yim GW, Kim S, Kim YT: The impact of pretreatment thrombocytosis and persistent thrombocytosis after adjuvant chemotherapy in patients with advanced epithelial ovarian cancer. Gynecol Oncol 2011, 122:238-241.
• [24]Alexandrakis MG, Passam FH, Moschandrea IA, Christophoridou AV, Pappa CA, Coulocheri SA, Kyriakou DS: Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol 2003, 26:135-140.
• [25]Gastl G, Plante M, Finstad CL, Wong GY, Federici MG, Bander NH, Rubin SC: High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Br J Haematol 1993, 83:433-441.
• [26]Suzuki A, Takahashi T, Nakamura K, Tsuyuoka R, Okuno Y, Enomoto T, Fukumoto M, Imura H: Thrombocytosis in patients with tumors producing colony-stimulating factor. Blood 1992, 80:2052-2059.
• [27]Bambace NM, Holmes CE: The platelet contribution to cancer progression. J Thromb Haemost 2011, 9:237-249.